GSK1 N Stock Overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£357.35 |
| 52 Week High | UK£357.35 |
| 52 Week Low | UK£357.35 |
| Beta | 0.27 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| GSK1 N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -6.1% | -2.2% |
| 1Y | n/a | -18.5% | 0.6% |
Return vs Industry: Insufficient data to determine how GSK1 N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how GSK1 N performed against the MX Market.
Price Volatility
| GSK1 N volatility | |
|---|---|
| GSK1 N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 1.7% |
Stable Share Price: GSK1 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GSK1 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 70,212 | Emma Walmsley | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
GSK plc Fundamentals Summary
| GSK1 N fundamental statistics | |
|---|---|
| Market cap | Mex$1.37t |
| Earnings (TTM) | Mex$104.17b |
| Revenue (TTM) | Mex$641.11b |
13.2x
P/E Ratio2.1x
P/S RatioIs GSK1 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSK1 N income statement (TTM) | |
|---|---|
| Revenue | UK£30.33b |
| Cost of Revenue | UK£8.39b |
| Gross Profit | UK£21.94b |
| Other Expenses | UK£17.01b |
| Earnings | UK£4.93b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 72.34% |
| Net Profit Margin | 16.25% |
| Debt/Equity Ratio | 131.4% |
How did GSK1 N perform over the long term?
See historical performance and comparison